Tes Pharma Presents Last Results on TES-AKI-01 at the 30th Annual International Conference on Advances in Critical Care Nephrology
Solomeo-Corciano (PG), Italy, February 28, 2025 – Tes Pharma, a biotech company focused on delivering first-in class therapeutics for high unmet medical needs in renal, metabolic and oncological diseases, today announced that an oral presentation will be delivered on the Company’s product candidate TES-AKI-01 at the 30th Annual International Conference on Advances in Critical Care Nephrology (AKI&CRRT) taking place March 3-6, 2025, in San Diego, CA.
“We are pleased to present our latest research in acute kidney injury (AKI) at such a large and reputable Conference” said Andrea Pellacani, Chief Medical Officer at Tes Pharma. “The results further support the concept of targeting of the de novo NAD+ biosynthesis by ACMSD inhibition as an innovative approach for the treatment of AKI and strengthen the therapeutic potential of TES-AKI-01, our development candidate, for the treatment of these acute clinical conditions for which no therapy is available”.
Title: Intravenous Administration of TES-AKI-01 Protects Kidney Function in a Rat Model of Acute Kidney Injury Induced by Bilateral Ischemia and Reperfusion
Lead Author: Giacchè Nicola PhD, ACMSD Project Leader, Tes Pharma
Session Title: Research in AKI: Translational Research (Oral Session 2)
Date/Time: Monday, March 3, 2025, from 5:30 p.m. – 7:30 p.m. PT
More information about this abstract will be made available after the respective embargoes, as set by the AKI&CRRT organizers, are lifted for each presentation. A full list of sessions at AKI&CRRT Conference 2025 is available at https://crrtonline.com/crrtconference/.
About TES-AKI-01
TES-AKI-01 is a potent and selective first in-class inhibitor of the α-Amino-β-Carboxymuconic-ε-Semialdehyde Decarboxylase (ACMSD) enzyme. ACMSD represents a branch point in the de novo NAD+ biosynthesis pathway. Dysregulation of de novo NAD+ biosynthesis with a consequent NAD+ decline may occur in kidneys, liver in various pathological conditions such as Acute Kidney Injury (AKI), MASH and acute inflammation, respectively. NAD+ replenishment by kidney/liver-specific de novo biosynthesis recovers essential cellular pathways, such as mitochondrial dysfunction and compromised energetic state. Treatment with TES-AKI-01 recovers NAD+ levels caused by increased energy demands in renal pathophysiological conditions, protecting the kidney from injury and promoting its recovery and functionality.
About Tes Pharma
Tes Pharma is a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in metabolic, renal diseases and oncology. Tes Pharma’s clinically validated drug discovery engine generates rationally designed drug candidates for novel targets. Tes Pharma has a long-standing partnership with Intercept for the discovery and development of bile acid derivatives for the treatment of liver disease. INT-787 is undergoing Phase 2 clinical studies for the treatment of severe alcohol-associated hepatitis (sAH). Separate from the collaboration with Intercept, Tes Pharma is also developing TES-AKI-01 and TES-ONC-07, two first-in-class small molecules for the treatment of acute kidney injury and for cancer immunotherapy, respectively, that are entering IND-enabling studies. Also, Tes Pharma has an undisclosed pipeline of additional projects in the early phase of drug discovery.
For more information, please visit www.tespharma.com or connect with the Company on LinkedIn
For further information, please contact:
Sara Malincarne
smalincarne@tespharma.com